- $722.30m
- $513.05m
Annexon Inc reports results for the quarter ended in December - Earnings Summary
Brief: Annexon Files For Mixed Shelf Offering Of Up To $400 Million - SEC Filing
Annexon Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Annexon- Outlines 2024 Priorities With Late-Stage Clinical Milestones Across Upstream Complement Portfolio
U.S. STOCKS ON THE MOVE-Cintas Corp, Carnival, Tri Pointe Homes
U.S. STOCKS ON THE MOVE-Emeren Group, Delta Airlines, Annexon Inc
Annexon surges as trial for treatment of autoimmune disease succeeds
Brief: Annexon Reports Phase 1 Results For Its Oral Small Molecule Inhibitor, Anx1502
Brief: Annexon Outlines Global Registrational Program For Anx007 In Geographic Atrophy With FDA Alignment On Vision Preservation As Primary Endpoint
Brief: Annexon Announces Pricing Of $125 mln Underwritten Public Offering Of Common Stock
U.S. RESEARCH ROUNDUP-Aclaris Therapeutics, Beauty Health Co, Vicarious Surgical
Annexon Inc expected to post a loss of 50 cents a share - Earnings Preview
Annexon rises on EMA's 'priority medicine' tag for eye disease treatment
U.S. STOCKS ON THE MOVE-Hyatt Hotels, Walmart, Maxeon
U.S. STOCKS ON THE MOVE-Olema Pharma, Akamai Technologies, US banks
Annexon up on EMA's 'orphan drug' tag for neurological disorder drug
Brief: Annexon Announces Clinical And Regulatory Progress For Anx005 Pivotal Program In Guillain-Barré Syndrome (GBS)
Annexon Inc reports results for the quarter ended in June - Earnings Summary
Brief: Annexon Biosciences Q2 basic EPS USD -0.47